Resetting neural networks through psilocybin-inspired therapies
Reset Pharma is a neuro-biotechnology company dedicated to improving mental health through novel pathways.
We exist to help people move beyond the psychological trauma of a life-threatening diagnosis.
Our focus lies where needs are most urgent: helping people overcome demoralization syndrome due to life-altering diseases, such as cancer.
We are breaking new scientific ground in collaboration with leading research institutions, including acquiring a worldwide license from NYU based on the seminal work of Stephen Ross, MD—a leading researcher in the field of psychedelic medicine and psycho-oncology.
To bring our treatment to market, Reset Pharma has established a highly experienced neuro-biotechnology team.
1. Grandjean J, Buehlmann D, Buerge M, et al. Psilocybin exerts distinct effects on resting state networks associated with serotonin and dopamine in mice. Neuroimage. 2020;225(2021):117456. doi:10.1016/j.neuroimage.2020.117456 2. Carhart-Harris RL, Roseman L, Bolstridge M, et al. Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. Sci Rep. 2021;7(1):13187. doi:10.1038/s41598-017-13282-7